Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

Allena Pharmaceuticals (ALNA) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 12 quarters since 2018. Compare with ALNA stock chart to see long term trends.

ALNA stock compared to

ALNA Income Statement

Research & Development Expense:6977000
Total Operating Expenses:9985000
Operating Income:-9985000
Net Income:-10258000
Earnings Per Share, Basic:-0.22
Shares Outstanding, Basic Avg:32506679

ALNA Cash Flow

Operating Activities Net Income:
Net Cash from Operations:-7830000
Net Cash from Financing Activities:13368000
Net Change in Cash & Equivalents:4906000

ALNA Balance Sheet

Cash and Cash Equivalents:35042000
Total Current Assets:37249000
Property, Plant & Equipment, Net:881000
Total Assets:38931000
Accounts Payable:2410000
Total Short-Term Liabilities:6122000
Total Liabilities:16362000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
FMR LLC
1,508,483 sh
32,600 sh
2%
$2,233
-$99
Morgan Stanley
1,051,627 sh
-28,758 sh
-3%
$1,556
-$151
Vanguard Group Inc
327,726 sh
-90,897 sh
-22%
$485
-$176
Jacobs Levy Equity Management, Inc
222,381 sh
95,709 sh
76%
$329
$129
Bridgeway Capital Management Inc
161,000 sh
 
$238
Blackrock Inc.
135,198 sh
1,656 sh
1%
$200
-$11
Goldman Sachs Group Inc
78,934 sh
50,822 sh
181%
$117
$73
Northern Trust Corp
28,803 sh
9,258 sh
47%
$43
$12
Bank Of America Corp /De/
5,400 sh
 
$8
Sabby Management, LLC
0 sh
-1,531,446 sh
-100%
$0
-$2,420
Renaissance Technologies LLC
0 sh
-617,270 sh
-100%
$0
-$975
Proequities, Inc.
0 sh
 
$0

Data imported from Allena Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.